Treatment of amyloidogenic diseases

• US 8,784,810 B2
• Filed: 10/17/2008
• Issued: 07/22/2014
• Est. Priority Date: 04/18/2006
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Original Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Wyeth LLC (Pfizer Inc.)
• Inventors: Lieberburg, Ivan, Callaway, James, Grundman, Michael
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US13/123,898
• Publication Number:
  US 20110229413A1
• Time in Patent Office: 2,104 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer'"'"'s disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

Claims

1. A method of treating Alzheimer'"'"'s disease, comprising:

subcutaneously administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ

, wherein the antibody is a humanized antibody comprising three light chain CDRs and three heavy chain CDRs of mouse antibody 3D6 expressed by the hybridoma deposited under ATCC under No. PTA-5130, and wherein the antibody is administered at a dosage within a range of 0.05-0.25 mg/kg and a frequency of between weekly and monthly, thereby treating the patient.

2. The method of claim 1, wherein the humanized-antibody is bapineuzumab.